Laboratory Screening of Lorcaserin for Alcohol Use Disorder
Status:
Terminated
Trial end date:
2020-02-26
Target enrollment:
Participant gender:
Summary
Heavy-drinking smokers, including those with alcohol use disorder (AUD), are at increased
risk for numerous negative health outcomes relative to those who use alcohol or cigarettes
only. Although heavy-drinking smokers are recognized as an important subgroup for clinical
and public health interventions, there are presently no approved medications for the joint
indication of alcohol reduction and smoking cessation. Based on evidence that the serotonin
system plays a role in alcohol and nicotine consumption and relapse, this study aims to
examine whether a serotonin medication alters alcohol and nicotine responses in smokers with
AUD, informing its potential utility as a candidate therapy for this clinical subgroup.